The major objective of the Biostatistics and Bioinformatics Core (Core 3) is to provide centralized biostatistics, bioinformatics, and database support for all Projects and Cores. Core 3 will provide guidance in the design and conduct of clinical trials and other experiments that arise from the ongoing research of the SPORE, facilitate prospective collection, entry, quality control, and integration of data for the basic science, pre-clinical, and clinical studies, and provide bioinformatics data analysis of high-throughput and high-dimensional genomics data. We will provide innovative and tailored statistical modeling, simulation techniques, and data analyses for the main projects, developmental research and career enhancement projects, and other cores to achieve their specific aims. We will conduct data analyses and prepare statistical reports for all experiments within all projects, ensure that the results of all projects are appropriately interpreted, and assist all project investigators in the publication of scientific results. Core 3 will also be a resource for intra- and inter-SPORE collaborations, including study design and developing databases for multi-center clinical trials.

Public Health Relevance

The Biostatistics and Bioinformatics Core provides consultation and collaboration in the design, conduct, analysis, and interpretation of research studies in this SPORE, helps them achieve their objectives and ensures scientifically valid conclusions will be drawn. Effective formulation and application of efficacy, futility and safety monitoring rules for clinical trials will offer protection to patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-18
Application #
10006810
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2003-08-05
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946
Boddu, Prajwal; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59:790-802
Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Zhang, Hanghang; Pandey, Somnath; Travers, Meghan et al. (2018) Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell 175:1244-1258.e26
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Fiorini, Elena; Santoni, Andrea; Colla, Simona (2018) Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11
Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut et al. (2018) Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 19:889-903

Showing the most recent 10 out of 487 publications